{"success":true,"data":{"pressRelease":{"id":"138871","rtpr_id":"nACS3GYfVa-20260909","ticker":"MBX","exchange":"TSX","all_tickers":["MBX"],"title":"Microbix Qualifies as Supplier for Five Major Dx Test-Makers Product Lines for Support of Leading IVD Manufacturers","author":"ACCESSWIRE","published_at":"2026-09-09T11:00:03.795Z","article_body":"MISSISSAUGA, ON / ACCESS Newswire (https://www.accessnewswire.com/) /\nSeptember 9, 2026 / Microbix Biosystems Inc.\n(TSX:MBX)(OTCQX:MBXBF)(Microbix®), a life sciences innovator, manufacturer,\nand exporter, announces that it has completed formal qualification to become a\nsupplier for five in-vitro diagnostics (IVD) manufacturers (\"Dx Test-Makers\").\nEach of these five Dx Test-Makers are considered to be one of the ten largest\nsuch companies by revenues, and Microbix is pleased to have successfully\ncompleted their supplier audit & quality review processes.\n\nClearing these detailed and multifaceted supplier qualification processes\npermits Microbix to supply critical products to these Dx Test-makers, across\nits antigens, QAPs™, ONBOARDx™ kits, QUANTDx® reference materials, and\nreagents. In multiple instances, these processes have involved multi-day\non-site audits of Microbix's manufacturing, quality control, quality\nassurance, ISO compliance, and other business systems.\n\nFormal supplier qualification does not guarantee that Microbix will be awarded\nmaterial contracts from these five Dx Test-Makers. However, it should ensure\nthat opportunities for such business will be more available to Microbix when\nnew projects arise. Additionally, being recognized as a fully-vetted supplier\nby such large and respected Dx Test-Makers may help Microbix secure business\nwith smaller diagnostics companies that lack the resources to conduct such\nrigorous supplier qualification processes.\n\nMicrobix believes major Dx Test-Makers do not typically commit resources to\naudit and qualify new suppliers without a clear business reason. While\nrespecting all confidentiality provisions, we can state their actions\ngenerally reflect interest in one or more of the following Microbix products\nor product lines:\n*\nAntigens. Purchase of Microbix's native or recombinant antigens to enable the\nproduction of tests for assessing prior exposure to, immunity from, or an\nacute reaction to, an infectious pathogen.\n*\nQAPs. Purchase of one or more of Microbix's QAPs patient-sample mimetics as\nin-kit test-controls to help ensure the accuracy of lab-based or point-of-need\ninfectious-disease tests.\n*\nONBOARDx kits. Purchase of customized kits of Microbix QAPs to assist with\nqualifying new testing sites and for the initial and periodic training of\ntechnicians at those sites.\n*\nQUANTDx. Purchase of well-characterized and quantified QUANTDx \"reference\nmaterials\" to assist with new assay development and as QC release standards\nfor the manufacture of assays.\n\nCameron Groome, CEO & President of Microbix commented, \"Focus on 'Customer\nSuccess' is helping us join our team with those of our clients - from initial\nassay concept through to full commercialization. We're grateful to have been\ninvited to undertake these qualification processes and are pleased to have\nsuccessfully concluded them. I commend the Microbix team for positively\nsupporting due diligence by five major firms and we certainly aim to secure\nand disclose new business with one or more of them.\"\n\nFurther information about Microbix antigens, QAPs, reference materials, and\nreagents is available at https://microbix.com, while purchase enquiries can be\ne-mailed to customer.service@microbix.com.\n\nAbout Microbix Biosystems Inc.\n\nMicrobix Biosystems Inc. creates proprietary biological products for human\nhealth, with 120 skilled employees and revenues of C$ 18.6 million in its\nlatest fiscal year (2025). It makes a wide range of critical ingredients and\ndevices for the global diagnostics industry, notably antigens for immunoassays\nand its laboratory quality assessment products (QAPs™) and reference\nmaterials (QUANTDx®) that support clinical lab proficiency testing, enable\nassay development and validation, or help ensure the quality of clinical\ndiagnostic workflows. Its antigens drive the antibody tests of approximately\n100 diagnostics makers, while QAPs or QUANTDx are sold to clinical lab PT/EQA\norganizations, diagnostics companies, and clinical labs. Microbix QAPs are now\navailable in over 30 countries, supported by international distributors.\nMicrobix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA\nregistered, Health Canada licensed, and provides IVDR-compliant CE marked\nproducts.\n\nMicrobix also applies its biological expertise and infrastructure to develop\nother proprietary products and technologies, most notably Kinlytic®\nurokinase, a biologic thrombolytic drug used to treat blood clots, and\nreagents or medial to support diagnostic testing (e.g., its DxTM® for\npatient-sample collection). Microbix is traded on the TSX and OTCQX, and\nheadquartered in Mississauga, Ontario, Canada.\n\nForward-Looking Information\n\nThis news release includes \"forward-looking information,\" as such term is\ndefined in applicable securities laws. Forward-looking information includes,\nwithout limitation, discussion of the Dx Test-Makers, their objectives, or\ntheir relevance, Microbix's or others' products or services, business and\nbusiness results, goals or outlook, risks associated with financial results\nand stability, development projects such as those referenced in its\npresentations, regulatory compliance and approvals, access to and sales to\nforeign jurisdictions, engineering and construction, production (including\ncontrol over costs, quality, quantity or timeliness of delivery), currency\nexchange rates, maintaining adequate working capital or raising new capital on\nacceptable terms or at all, and other similar statements about anticipated\nfuture events, conditions or results that are not historical facts. These\nstatements reflect management's current estimates, beliefs, intentions, and\nexpectations; they are not guarantees of future performance. Microbix cautions\nthat all forward-looking information is inherently uncertain and actual\nperformance may be affected by many material factors, some of which are beyond\nits control. Accordingly, actual future events, conditions and results may\ndiffer materially from the estimates, beliefs, intentions, and expectations\nexpressed or implied in the forward-looking information. All statements are\nmade as of the date of this news release and represent Microbix's judgement as\nof the date of this new release, and it is under no obligation to update or\nalter any forward-looking information except as required by applicable law.\n\nPlease visit https://microbix.com or https://www.sedarplus.ca for recent\nMicrobix news and filings.\n\nFor further information, please contact Microbix at:\n\nCameron Groome, CEO\n(905) 361-8910\n\nJim Currie, CFO\n(905) 361-8910\n\nDeborah Honig\nInvestor Relations\nAdelaide Capital Markets\n(647) 203-8793\nir@microbix.com\n\nCopyright © 2026 Microbix Biosystems Inc.\n\nMicrobix®, DxTM®, Kinlytic®, ONBOARDx™, QAPs™, and QUANTDx® are\ntrademarks of Microbix Biosystems Inc.\n\nSOURCE: Microbix Biosystems Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/biotechnology/microbix-qualifies-as-supplier-for-five-major-dx-test-makers-product-lines-for-suppor-1218232)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACS3GYfVa-20260909","title":"Microbix Qualifies as Supplier for Five Major Dx Test-Makers Product Lines for Support of Leading IVD Manufacturers","author":"ACCESSWIRE","ticker":"MBX","created":"2026-09-09T11:00:03.795Z","tickers":["MBX"],"exchange":"TSX","article_body":"MISSISSAUGA, ON / ACCESS Newswire (https://www.accessnewswire.com/) /\nSeptember 9, 2026 / Microbix Biosystems Inc.\n(TSX:MBX)(OTCQX:MBXBF)(Microbix®), a life sciences innovator, manufacturer,\nand exporter, announces that it has completed formal qualification to become a\nsupplier for five in-vitro diagnostics (IVD) manufacturers (\"Dx Test-Makers\").\nEach of these five Dx Test-Makers are considered to be one of the ten largest\nsuch companies by revenues, and Microbix is pleased to have successfully\ncompleted their supplier audit & quality review processes.\n\nClearing these detailed and multifaceted supplier qualification processes\npermits Microbix to supply critical products to these Dx Test-makers, across\nits antigens, QAPs™, ONBOARDx™ kits, QUANTDx® reference materials, and\nreagents. In multiple instances, these processes have involved multi-day\non-site audits of Microbix's manufacturing, quality control, quality\nassurance, ISO compliance, and other business systems.\n\nFormal supplier qualification does not guarantee that Microbix will be awarded\nmaterial contracts from these five Dx Test-Makers. However, it should ensure\nthat opportunities for such business will be more available to Microbix when\nnew projects arise. Additionally, being recognized as a fully-vetted supplier\nby such large and respected Dx Test-Makers may help Microbix secure business\nwith smaller diagnostics companies that lack the resources to conduct such\nrigorous supplier qualification processes.\n\nMicrobix believes major Dx Test-Makers do not typically commit resources to\naudit and qualify new suppliers without a clear business reason. While\nrespecting all confidentiality provisions, we can state their actions\ngenerally reflect interest in one or more of the following Microbix products\nor product lines:\n*\nAntigens. Purchase of Microbix's native or recombinant antigens to enable the\nproduction of tests for assessing prior exposure to, immunity from, or an\nacute reaction to, an infectious pathogen.\n*\nQAPs. Purchase of one or more of Microbix's QAPs patient-sample mimetics as\nin-kit test-controls to help ensure the accuracy of lab-based or point-of-need\ninfectious-disease tests.\n*\nONBOARDx kits. Purchase of customized kits of Microbix QAPs to assist with\nqualifying new testing sites and for the initial and periodic training of\ntechnicians at those sites.\n*\nQUANTDx. Purchase of well-characterized and quantified QUANTDx \"reference\nmaterials\" to assist with new assay development and as QC release standards\nfor the manufacture of assays.\n\nCameron Groome, CEO & President of Microbix commented, \"Focus on 'Customer\nSuccess' is helping us join our team with those of our clients - from initial\nassay concept through to full commercialization. We're grateful to have been\ninvited to undertake these qualification processes and are pleased to have\nsuccessfully concluded them. I commend the Microbix team for positively\nsupporting due diligence by five major firms and we certainly aim to secure\nand disclose new business with one or more of them.\"\n\nFurther information about Microbix antigens, QAPs, reference materials, and\nreagents is available at https://microbix.com, while purchase enquiries can be\ne-mailed to customer.service@microbix.com.\n\nAbout Microbix Biosystems Inc.\n\nMicrobix Biosystems Inc. creates proprietary biological products for human\nhealth, with 120 skilled employees and revenues of C$ 18.6 million in its\nlatest fiscal year (2025). It makes a wide range of critical ingredients and\ndevices for the global diagnostics industry, notably antigens for immunoassays\nand its laboratory quality assessment products (QAPs™) and reference\nmaterials (QUANTDx®) that support clinical lab proficiency testing, enable\nassay development and validation, or help ensure the quality of clinical\ndiagnostic workflows. Its antigens drive the antibody tests of approximately\n100 diagnostics makers, while QAPs or QUANTDx are sold to clinical lab PT/EQA\norganizations, diagnostics companies, and clinical labs. Microbix QAPs are now\navailable in over 30 countries, supported by international distributors.\nMicrobix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA\nregistered, Health Canada licensed, and provides IVDR-compliant CE marked\nproducts.\n\nMicrobix also applies its biological expertise and infrastructure to develop\nother proprietary products and technologies, most notably Kinlytic®\nurokinase, a biologic thrombolytic drug used to treat blood clots, and\nreagents or medial to support diagnostic testing (e.g., its DxTM® for\npatient-sample collection). Microbix is traded on the TSX and OTCQX, and\nheadquartered in Mississauga, Ontario, Canada.\n\nForward-Looking Information\n\nThis news release includes \"forward-looking information,\" as such term is\ndefined in applicable securities laws. Forward-looking information includes,\nwithout limitation, discussion of the Dx Test-Makers, their objectives, or\ntheir relevance, Microbix's or others' products or services, business and\nbusiness results, goals or outlook, risks associated with financial results\nand stability, development projects such as those referenced in its\npresentations, regulatory compliance and approvals, access to and sales to\nforeign jurisdictions, engineering and construction, production (including\ncontrol over costs, quality, quantity or timeliness of delivery), currency\nexchange rates, maintaining adequate working capital or raising new capital on\nacceptable terms or at all, and other similar statements about anticipated\nfuture events, conditions or results that are not historical facts. These\nstatements reflect management's current estimates, beliefs, intentions, and\nexpectations; they are not guarantees of future performance. Microbix cautions\nthat all forward-looking information is inherently uncertain and actual\nperformance may be affected by many material factors, some of which are beyond\nits control. Accordingly, actual future events, conditions and results may\ndiffer materially from the estimates, beliefs, intentions, and expectations\nexpressed or implied in the forward-looking information. All statements are\nmade as of the date of this news release and represent Microbix's judgement as\nof the date of this new release, and it is under no obligation to update or\nalter any forward-looking information except as required by applicable law.\n\nPlease visit https://microbix.com or https://www.sedarplus.ca for recent\nMicrobix news and filings.\n\nFor further information, please contact Microbix at:\n\nCameron Groome, CEO\n(905) 361-8910\n\nJim Currie, CFO\n(905) 361-8910\n\nDeborah Honig\nInvestor Relations\nAdelaide Capital Markets\n(647) 203-8793\nir@microbix.com\n\nCopyright © 2026 Microbix Biosystems Inc.\n\nMicrobix®, DxTM®, Kinlytic®, ONBOARDx™, QAPs™, and QUANTDx® are\ntrademarks of Microbix Biosystems Inc.\n\nSOURCE: Microbix Biosystems Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/biotechnology/microbix-qualifies-as-supplier-for-five-major-dx-test-makers-product-lines-for-suppor-1218232)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-09-09T11:00:03.856723077Z","server_sent_at_ms":1788951603856},"received_at":"2026-09-09T11:00:03.908Z","source_url":"https://www.accessnewswire.com/newsroom/en/biotechnology/microbix-qualifies-as-supplier-for-five-major-dx-test-makers-product-lines-for-suppor-1218232"},"analysis":{"id":"127705","press_release_id":"138871","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Formal supplier qualification does not guarantee material contracts from the five Dx test-makers","No revenue, volume, or timeline figures attached to the qualification milestone","Company remains small relative to target customers (C$18.6M FY2025 revenue)"],"eventType":"operations_update","narrative":"Microbix Biosystems has completed formal supplier qualification with five in-vitro diagnostics manufacturers, each ranked among the ten largest Dx test-makers by revenue.\n\nThe qualification clears Microbix to supply antigens, QAPs, ONBOARDx kits, QUANTDx reference materials, and reagents to these majors, though the company explicitly notes it does not guarantee material contracts from any of the five firms.\n\nMicrobix generated C$18.6 million in revenue in fiscal 2025 with 120 employees, and its antigens currently drive antibody tests for roughly 100 diagnostics makers across more than 30 countries for its QAPs products.\n\nCEO Cameron Groome said the successful multi-day audits reflect genuine commercial interest and that Microbix aims to secure and disclose new business with one or more of the newly qualified customers.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Five top-10 IVD makers completed full supplier audits of Microbix -- watch for follow-on contract disclosures as the actual catalyst."},"keyFigures":{"revenue":"C$18.6 million","customDimensions":{"employees":120,"countries_qap_available":30,"qualified_dx_test_makers":5,"fiscal_year_revenue_period":"FY2025","diagnostics_makers_using_antigens":100}},"quotedText":"Microbix believes major Dx Test-Makers do not typically commit resources to\naudit and qualify new suppliers without a clear business reason.","namedEntities":{"people":[{"name":"Cameron Groome","role":"CEO & President"},{"name":"Jim Currie","role":"CFO"},{"name":"Deborah Honig","role":"Investor Relations, Adelaide Capital Markets"}],"products":["Antigens","QAPs","ONBOARDx kits","QUANTDx reference materials","Kinlytic urokinase","DxTM"],"companies":[{"name":"Microbix Biosystems Inc.","ticker":"MBX","relationship":"filer"},{"name":"Adelaide Capital Markets","relationship":"investor relations firm"}],"dollarAmounts":[{"amount":"C$ 18.6 million","context":"Microbix revenue in its latest fiscal year (2025)"}]},"materialImpact":{"score":2,"reasoning":"Completing supplier qualification at five top-10 IVD manufacturers is a meaningful validation milestone for a small-cap diagnostics supplier, but the release explicitly states it does not guarantee material contracts and discloses no associated revenue. Impact is optionality, not booked business."},"tickerRelevance":{"others":[{"ticker":"MBXBF","relevance":"OTCQX listing of the same company"}],"primary":"MBX"},"globalImportance":18,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap (TSX-listed, ~C$18.6M revenue)","eventGravity":"supplier-qualification milestone, no contracts signed","sectorWeight":"niche diagnostics ingredients supplier","householdBrandBoost":0,"retailFavoriteBoost":0,"contractNotGuaranteed":true}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Microbix Biosystems has completed formal supplier qualification with five in-vitro diagnostics manufacturers, each ranked among the ten largest Dx test-makers by revenue.\n\nThe qualification clears Microbix to supply antigens, QAPs, ONBOARDx kits, QUANTDx reference materials, and reagents to these majors, though the company explicitly notes it does not guarantee material contracts from any of the five firms.\n\nMicrobix generated C$18.6 million in revenue in fiscal 2025 with 120 employees, and its antigens currently drive antibody tests for roughly 100 diagnostics makers across more than 30 countries for its QAPs products.\n\nCEO Cameron Groome said the successful multi-day audits reflect genuine commercial interest and that Microbix aims to secure and disclose new business with one or more of the newly qualified customers.","key_figures":{"revenue":"C$18.6 million","customDimensions":{"employees":120,"countries_qap_available":30,"qualified_dx_test_makers":5,"fiscal_year_revenue_period":"FY2025","diagnostics_makers_using_antigens":100}},"named_entities":{"people":[{"name":"Cameron Groome","role":"CEO & President"},{"name":"Jim Currie","role":"CFO"},{"name":"Deborah Honig","role":"Investor Relations, Adelaide Capital Markets"}],"products":["Antigens","QAPs","ONBOARDx kits","QUANTDx reference materials","Kinlytic urokinase","DxTM"],"companies":[{"name":"Microbix Biosystems Inc.","ticker":"MBX","relationship":"filer"},{"name":"Adelaide Capital Markets","relationship":"investor relations firm"}],"dollarAmounts":[{"amount":"C$ 18.6 million","context":"Microbix revenue in its latest fiscal year (2025)"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-09T11:07:14.736Z","global_importance":18,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap (TSX-listed, ~C$18.6M revenue)","eventGravity":"supplier-qualification milestone, no contracts signed","sectorWeight":"niche diagnostics ingredients supplier","householdBrandBoost":0,"retailFavoriteBoost":0,"contractNotGuaranteed":true}},"durationMs":39610,"modelName":"glm-5.3-flash"}}